Skip to main content

Table 2 Tumor and treatment characteristics

From: 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

 

FDG study (N = 22)

FLT study (N = 27)

N (%)

Mean (range)

N (%)

Mean (range)

Diagnosis

 Invasive ductal

20 (91%)

 

20 (74%)

 

 Invasive lobular

2 (9%)

 

7 (26%)

 

Tumor size (cm)

 

2.6 (0.7–7.5)

 

3.1 (1.1–7.6)*

T Stage

 T1

9 (41%)

 

8 (30%)

 

 T2

12 (55%)

 

15 (56%)

 

 T3

1 (5%)

 

3 (11%)

 

 X

–

 

1 (4%)

 

ER+

22 (100%)

 

27 (100%)

 

PR+

20 (91%)

 

22 (81%)

 

Her2-

22 (100%)

 

26 (96%)†

 

Ki-67 (Biopsy)

 All

 

25.4 (1.0–72.9)

 

20.6 (4–54)

 Ductal

 

26.5 (1–72.9)

 

23.5 (6–54)

 Lobular

 

14 (9.2–18.8)

 

12.3 (4–23)

Ki-67 (at surgery)

 All

 

8.7 (1.0–31.4)

 

7.9 (0–41)

 Ductal

 

9.1 (< 1.0–31.4)

 

9.3 (0–41)

 Lobular

 

4.4 (3–5.9)

 

4.1 (0–20.3)

Ki-67 ≤ 10% (at surgery)

 All

17 (77%)

 

21 (78%)

 

Ductal

15 (75%)

 

15 (75%)

 

 Lobular

2 (100%)

 

6 (86%)

 
  1. *Tumor sized by MRI in all but one patient. That patient had a lesion size of 1.1 cm by contrast enhanced CT
  2. †1 patient was scored as HER2 equivocal, but no plan for treatment change